Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDS0101 in CIN and High-risk HPV
NCT02065973Phase 1Completed
- Sponsor
- PDS Biotech
- Start
- Feb 2014
- Primary completion
- Dec 2015
- Modality
- Peptides, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of PDS0101 in cervical intraepithelial neoplasia (CIN) and human papillomavirus infection (3 cohorts), sponsored by PDS Biotech. Primary endpoint: Evaluation or determination of adverse events following vaccination. Started Feb 2014; status: completed.
02
Drugs
PDS0101
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on NCT02065973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02065973.